Chief executive of Array BioPharma resigns

Chairman Kyle Lefkoff will lead effort to replace Robert Conway

Robert Conway has resigned as chief executive of Array BioPharma, a US biotechnology company, for personal reasons. The board has appointed chairman Kyle Lefkoff to serve as executive chairman to oversee the company in the interim and lead the effort to identify a new chief executive.

Lefkoff said he will work with the Array management team to ensure a smooth transition and continued advancement of the company’s multiple clinical programmes in cancer and inflammation and supporting our many partnered programmes.

You may also like

Research & Development

Array Biopharma and Genentech to progress ChK-1 programme

Genentech will pay US$28m upfront payment to Array
Finance

Array BioPharma to cut jobs in restructure

Will focus on development of key clinical programmes
Research & Development

Array BioPharma signs strategic oncology collaboration

Agreement with Novartis will advance aim to become integrated, commercial-stage biopharma company
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Regulatory

Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China

The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
Manufacturing

Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company

The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
Packaging

Dual-chamber packaging systems as a simplification factor in the supply chain

Dual-chamber packaging solutions could represent a new frontier also to package parenteral drugs, simplifying the supply chain through reconstitution, potentially making logistics more flexible and efficient, says Cecilia Bassi, Product Manager at Bormioli Pharma
Subscribe now